medigraphic.com
ISSN 0035-0052 (Print)

2009, Number 4

<< Back Next >>

Rev Mex Pediatr 2009; 76 (4)

Treatment of Hodgkin’s lymphoma in children, using the scheme COP-ABVD

Quero-Hernández A, Álvarez-Solís RM, Vargas-Vallejo M, Ellis-Irigoyen A, Fenton NP, Tenorio-Rodríguez H, Estrada CR

Language: Spanish
References: 20
Page: 165-169
PDF size: 78.94 Kb.


ABSTRACT

Objective. To evaluate the Hodgkin's disease treatment in children of two hospitals. Patients and methods. Twenty eight clinical files of Hodgkin’s disease patients were analyzed, according to the stage on the disease, 24 patients received chemotherapy. The strategy was: Cyclophosphamide, vincristine, prednisone (COP), adriamycine, bleomicine, vinblastine, dacarbazine (ABVD). Results. Age averaged was 7.7 years age 12 were in III and IV stages, and the percentage of surviving outcome at 52 months was 92% in the chemotherapy group. Four patients in the «B» stage beside chemotherapy received radiotherapy with a similar overcome (90%). Conclusion. The chemotherapy without radiotherapy by itself could be an option for the future management of these children.


REFERENCES

  1. DeVita V, Mautch P, Harris NL. Enfermedad de Hodgkin. En: DeVita Vincent, Hellman S, Rosenberg S, Editors. Cáncer, principios y práctica de Oncología. Philadelphia: Lippincott Williams & Wilkins 2000; 2: 2242-83.

  2. Harris NL, Jaffe SS, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group (see comments). Blood 1994; 84: 1361-92.

  3. MacMahon B. Epidemiology of Hodgkin’s disease. Cancer Res 1966; 26(61): 1189-1200.

  4. Hudson MM, Donaldson S. Hodgkin’s disease. In: Philip A, Pizzo, David G, Poplack, Editors. Principles and practice of Pediatric Oncology 3rd Ed. Philadelphia, NY. Lippincott Raven. 997: 523-43.

  5. Rivera-Luna R, Leal-Leal C, Cárdenas-Cardós R. A survey of 4,706 children with cancer. Certain epidemiological aspects from a single Institution. Bol Med Hosp Infant Mex 1996; 53: 598-604.

  6. Olaya-Vargas A. Linfoma de Hodgkin. En: Rivera-Luna R. Editor. Hemato-oncología pediátrica. Principios generales. México: ETM. 2006: 301-16.

  7. Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low-dose envolved-field radiotherapy in pediatric Hodgkin’s disease: The Stanford experience. J Clin Oncol 1994; 12: 2160-6.

  8. Rock DB, Murray KJ, Schultz CJ, Christopher J, Lauers SJ, Wilson JF. Stage I and II Hodgkin’s disease in the pediatric population: Long-term follow-up of patients staged predominantly clinically. Am J Clin Oncol 1996; 19(2): 174-8.

  9. Bonadonna G, Zucali R, Monfardini S, de Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with Adriamycin, bleomycin, vinblastina, and imidazole carboxamide versus MOPP. Cancer 1975; 36(1): 252-9.

  10. Canellos GP, Anderson JIR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327(21): 1478-84.

  11. Kaplan EL, Meier P. Non-parametric estimation of incomplete observations. J Am Stat Assoc 1958; 53: 270-83.

  12. Ron SS, Quing C, Melissa MH, Michael PL, Larry K, Howard W, Amy B, et al. Prognostic factors for children with Hodgkin’s disease treated with combined-modality therapy. J Clin Oncol 2003; 21: 2026-33.

  13. James BN, Nachman RS, Philip H, Gerald S, Gilchrist S, Wolden JT, et al. Randomized comparison of low-dose envolved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20: 3765-71.

  14. Dores GM, Metayer C, Curtis RE Lynch FE, Clark EA, Bengt G, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 2002; 20: 3484-94.

  15. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock A, et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort the relation to age at treatment. J Clin Oncol 2000; 18: 498-509.

  16. Metayer C, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol 2000; 18: 2435-43.

  17. Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin 2004; 54: 208-36.

  18. Schellong G, Potter R, Brämswig J, Wagner W, Prott FJ, Dörffel W, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: The German-Austrian multicenter trial DAL-HD-90. J Clin Oncol 1999; 17: 3737-44.

  19. Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, et al. Randomized study of intensive MOPP-AVBD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB and IV Hodgkin’s disease in pediatric patients: A pediatric oncology group study. J Clin Oncol 1997; 15: 2769-79.

  20. Loeffler M, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, et al. Meta-analysis of chemotherapy versus combination treatment in Hodgkin’s disease: International database on Hodgkin’s disease overview study group. J Clin Oncol 1998; 16: 818-29.




2020     |     www.medigraphic.com